FDA taps acting generics chief in wake of Geba's exit; Boehringer, Lilly launch new Trajenta trial;

@FiercePharma: Krystexxa sales still aren't taking off. Savient says Q4 sales of gout drug only up to $4.7M from $3M. Report | Follow @FiercePharma

@EricPFierce: Italy's the 2nd largest API maker behind China, says Italian expert. Who would have guessed it? India is 3rd. More | Follow @EricPFierce

> FDA Commissioner Margaret Hamburg picked Dr. Kathleen Uhl to serve as acting chief of the agency's generic drugs office; she replaces her former boss, Dr. Gregory Geba, who resigned last week. Report

> Boehringer Ingelheim and Eli Lilly ($LLY) launched a late-stage trial of their diabetes drug Trajenta in patients with kidney damage. Report

> Drug sales in France are expected to continue shrinking this year as the government cuts healthcare spending. Report

> AstraZeneca ($AZN) may consider leasing three lab buildings in Delaware, rather than demolishing them as originally planned, local officials said. Report

> A real estate developer may buy Bayer HealthCare's campus near Wayne, NJ, to market it as an office and R&D facility. Report

> Officials in Malta are working with Actavis to find jobs for the 65 workers laid off there earlier this month. Report

> Worried about their own insurance costs, Texas business groups are lobbying Gov. Rick Perry to sign on to President Obama's Medicaid expansion. Report

Biotech News

 @FierceBiotech: Amgen scores PhIII success with BioVex virus against melanoma. More | Follow @FierceBiotech

@JohnCFierce: AstraZeneca feels sting of union backlash against R&D upheaval. Story | Follow @JohnCFierce

@RyanMFierce: Merck slashes data-management costs with China site. Article | Follow @RyanMFierce

> Volatile BioLineRx shares decimated by PhII/III schizophrenia drug failure. Story

> Lone Star biotech banks $11.4M for PhII orphan drug odyssey. Article

> Amgen scores PhIII success with BioVex virus against melanoma. News

Medical Device News

 @FierceMedDev: Post-PMA, Cardiovascular Systems pursues public offering. More | Follow @FierceMedDev

 @MarkHFierce: Spurned by Illumina, Roche may have found a new gene sequencer/Dx company to love. But at what price? Story | Follow @MarkHFierce

 @DamianFierce: With election long passed, device tax lobbyists ply Dems. Article | Follow @DamianFierce

> Sorin eyes FDA approval with heart device trial. Article

> SynCardia snags $19M for artificial heart. Report

Biomarkers News

> Luminex to collaborate with Merck on Alzheimer's biomarker diagnostic. Report

> Mount Sinai wins $5M to study vocal disorder biomarkers. Item

> Pee in a cup to diagnose gastroesophageal cancer. More

> GenoMine test spots three new kidney cancer biomarkers. Article

> Texas research team spots Barrett's esophagus biomarkers. Story

Drug Delivery News

@MichaelGFierce: Spectrum picks up orphan cancer drug with stabilized delivery. More | Follow @MichaelGFierce

> New nanomed reduces inflammation in injured tissue by natural means. Story

> Delivery gel releases drugs in response to pressure. More

> Shire bets on PhII protein-delivery therapy to fight infant blindness. Article

> Needle-free ear infection patch delivers bacteria-killing vaccine. Item

And Finally... Several grocery chains have pledged not to sell genetically engineered salmon. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.